Trastuzumab duocarmazine

• CAT Number: I042125
• CAS Number: 1642152-40-6
• Purity: ≥95%

Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1].
Trastuzumab duocarmazine (SYD985) (0.0001-100 μg/mL, 24 h) is lethal to both HER2- and HER2+ cells, and is 7-fold more lethal to HER2/NEU3+ cell lines with the IC50 value of 0.013 μg/mL compared to T-DM1 with the IC50 value of 0.096 μg/mL. More importantly, in HER2/NEU1+ cells, it is 54 times more potent in killing cells compared to T-DM1[1].
Trastuzumab duocarmazine (SYD985) (3 mg/kg or 10 mg/kg, i.v., once) significantly inhibits tumor growth and prolongs the survival cycle in CB-17 / SCID mice with HER2/neu 3+ cells, with effective in vivo anti-tumor activity[1].

Reference

[1]. Gulden Menderes, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017 Oct 1;23(19):5836-5845.
 [Content Brief]